Cosmetic, prescription or experimental?
Understand the differences before comparing two peptide products.
Sources checked October 20, 2026 · US context · Human editorial and scientific review pending
The short answer
A peptide name alone does not tell you whether a product is a cosmetic, an authorized medicine or an experimental preparation. Intended use and the specific product matter.[1]
Cosmetics: read the formula
Cosmetics concern cleansing or appearance. Treatment claims can change a product’s legal classification; a cosmetic ingredient is not automatically a medicine.[1]
Medicines: check the exact authorization
Do not transfer an authorized medicine’s status to a compounded version or an online vial. FDA says compounded GLP-1 preparations do not undergo the same approval review.[2]
Experimental: distinguish a trial from an offer
A study is not a retail product approval. For example, FDA says retatrutide is not a component of an approved drug. A seller’s research-only label does not verify quality.[2]
Compare products within their actual use and evidence context. Peptivelo’s commercial comparator currently covers cosmetic serums.
References and access limitsStudy design, commercial context and what was inspected
- Regulatory guidanceIs It a Cosmetic, a Drug, or Both?
Evidence and limitations for reference 1
- What this supports here
- The US regulator’s stated distinction or risk communication at the inspection date.
- What it cannot establish
- Not a new clinical trial or a complete literature review. Regulatory statements have a jurisdiction, date and specific scope; absence of established safety is not proof of a particular injury.
- Commercial context and disclosures
- US government regulator; not a retailer.
- What we inspected
- Public source text inspected; underlying clinical dossiers not independently reanalysed.
- Regulatory guidanceFDA’s Concerns with Unapproved GLP-1 Drugs Used for Weight Loss
Evidence and limitations for reference 2
- What this supports here
- The US regulator’s stated distinction or risk communication at the inspection date.
- What it cannot establish
- Not a new clinical trial or a complete literature review. Regulatory statements have a jurisdiction, date and specific scope; absence of established safety is not proof of a particular injury.
- Commercial context and disclosures
- US government regulator; not a retailer.
- What we inspected
- Public source text inspected; underlying clinical dossiers not independently reanalysed.